Exhibit 10.17 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS ([**]), HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED...Co-Development and License Agreement • April 5th, 2004 • Viacell Inc • Services-commercial physical & biological research • Massachusetts
Contract Type FiledApril 5th, 2004 Company Industry Jurisdiction
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. CO-DEVELOPMENT AND LICENSE AGREEMENT Between...Co-Development and License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 28th, 2021 Company IndustryThis CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of June 14, 2013 (the “Effective Date”), is between AMBRX, Inc., a Delaware Corporation having the principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”), and , Zhejiang Medicine Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having the principal business address at 268 Dengyun Road, Gongshu District, Hangzhou, Zhejiang, P.R. China, for and on behalf of itself and its Affiliates (together with its Affiliates, “ZMC”). AMBRX and ZMC may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”
Co-development and License Agreement on NIP-022, a Novel Platelet Increasing AgentCo-Development and License Agreement • October 26th, 2015
Contract Type FiledOctober 26th, 2015Nissan Chemical Industries, Ltd. (Tokyo, Japan, President: Kojiro Kinoshita, “Nissan”) and Yakult Honsha Co., Ltd. (Tokyo, Japan, President: Takashige Negishi, “Yakult”) are pleased to announce that both companies have entered into a co-development and license agreement on NIP-022, a novel platelet increasing agent discovered by Nissan.
CO-DEVELOPMENT AND LICENSE AGREEMENT BY AND BETWEEN JANSSEN PHARMACEUTICA, N.V. AND MINERVA NEUROSCIENCES, INC. DATED FEBRUARY 13, 2014Co-Development and License Agreement • June 10th, 2014 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 10th, 2014 Company Industry JurisdictionTHIS CO-DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”), executed as of February 13, 2014 (the “Execution Date”), is made by and between Janssen Pharmaceutica, N.V., a corporation organized and existing under the laws of Belgium, having its principal place of business is at Turnhoutseweg 30, 2340 Beerse, Belgium (hereinafter “Janssen”), and Minerva Neurosciences, Inc., a corporation organized under the laws of the State of Delaware, having its principal place of business at 245 First Street, Cambridge, Massachusetts (hereinafter “Minerva”). Janssen and Minerva are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Arena, Ildong Pharma enter deal in South KoreaCo-Development and License Agreement • December 10th, 2022
Contract Type FiledDecember 10th, 2022
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CO-DEVELOPMENT AND LICENSE...Co-Development and License Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations • Hong Kong
Contract Type FiledJune 23rd, 2014 Company Industry JurisdictionThis CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of April 10, 2014 (the “Effective Date”), is between Ambrx, Inc., a Delaware Corporation having its principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”), and Zhejiang HISUN Pharmaceutical Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having its principal business address at 46 Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province, 318000, P.R. China, for and on behalf of itself and its Affiliates (together with its Affiliates, “HISUN”). AMBRX and HISUN may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. CO-DEVELOPMENT AND LICENSE...Co-Development and License Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations
Contract Type FiledJune 23rd, 2014 Company IndustryThis CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of June 14, 2013 (the “Effective Date”), is between AMBRX, Inc., a Delaware Corporation having the principal business address at 10975 North Torrey Pine Road, La Jolla, California 92037, USA for and on behalf of itself and its Affiliates (together with its Affiliates, “AMBRX”), and , Zhejiang Medicine Co., Ltd., a company duly organized and existing under the laws of the People’s Republic of China and having the principal business address at 268 Dengyun Road, Gongshu District, Hangzhou, Zhejiang, P.R. China, for and on behalf of itself and its Affiliates (together with its Affiliates, “ZMC”). AMBRX and ZMC may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”
CO-DEVELOPMENT AND LICENSE AGREEMENT among NOVOCODEX BIOPHARMACEUTICALS LTD. and AMBRX, INC. Dated as of 22 October, 2019Co-Development and License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances) • Hong Kong
Contract Type FiledMay 28th, 2021 Company Industry JurisdictionThis CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of 22 October, 2019 (the “Effective Date”), is between, Ambrx, Inc., a Delaware corporation having its principal business address at 10975 North Torrey Pines Road, La Jolla, California 92037, USA, for and on behalf of itself and its Affiliates (together with its Affiliates, “Ambrx”), and NovoCodex Biopharmaceuticals Ltd., a company registered under the laws of the People’s Republic of China, with its registered address in Shaoxing, China, for and on behalf of itself and its Affiliates (together with its Affiliates, “Novocodex”). Novocodex currently is majority owned by Zhejiang Medicine Co. Ltd., a company registered with address in Shaoxing, China. Ambrx and Novocodex may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”
CO-DEVELOPMENT AND LICENSE AGREEMENT between NEOTHERAPEUTICS, INC. and GPC BIOTECH AG Dated as of September 30, 2002Co-Development and License Agreement • June 9th, 2004 • GPC Biotech Ag • Massachusetts
Contract Type FiledJune 9th, 2004 Company JurisdictionThis CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), dated as of September 30, 2002, is between Neotherapeutics, Inc., a company duly organized and existing under the laws of Delaware and having offices at 157 Technology Drive, Irvine, California, USA for and on behalf of itself and its Affiliates (“NEOTHERAPEUTICS”), and GPC Biotech AG, a company duly organized and existing under the laws of the Federal Republic of Germany and having offices at Fraunhoferstrasse 20, D-82152 Martinsried/Munich Germany, for and on behalf of itself and its Affiliates (together with its Affiliates, “GPC”).
EXHIBIT 10.1 Confidential treatment has been requested for portions of this Exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [Intentionally Redacted]. A complete version of this...Co-Development and License Agreement • November 15th, 2004 • Spectrum Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
Contract Type FiledNovember 15th, 2004 Company Industry Jurisdiction
CO-DEVELOPMENT AND LICENSE AGREEMENTCo-Development and License Agreement • March 16th, 2006 • Pharmion Corp • Pharmaceutical preparations • New York
Contract Type FiledMarch 16th, 2006 Company Industry JurisdictionThis Co-Development and License Agreement (the “Agreement”) is made and entered into effective as of December 19, 2005 (the “Effective Date”) by and between GPC Biotech AG, a German corporation, having its place of business at Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany (“GPC Biotech”); and Pharmion GmbH, a Swiss limited liability company and wholly-owned subsidiary of Pharmion Corporation, a Delaware corporation, having a place of business at Aeschenvorstadt 71, 4051 Basel, Switzerland (“Licensee”). GPC Biotech and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CO-DEVELOPMENT AND LICENSE AGREEMENTCo-Development and License Agreement • April 26th, 2011 • Cell Therapeutics Inc • Pharmaceutical preparations • England and Wales
Contract Type FiledApril 26th, 2011 Company Industry Jurisdiction** Indicates that certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
CO-DEVELOPMENT AND LICENSE AGREEMENT between SINO BIOPHARMACEUTICAL CO., LTD. and AMBRX, INC. Dated as of January 13, 2020Co-Development and License Agreement • May 28th, 2021 • Ambrx Biopharma Inc. • Biological products, (no disgnostic substances) • Hong Kong
Contract Type FiledMay 28th, 2021 Company Industry JurisdictionThis CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), effective as of January 13, 2020 (the “Effective Date”), is between Ambrx, Inc., a Delaware corporation having its principal business address at 10975 North Torrey Pines Road, La Jolla, California 92037, USA, for and on behalf of itself and its Affiliates (together with its Affiliates, “Ambrx”), and Sino Biopharmaceutical Co., Ltd., a company registered under the laws of the Cayman Islands, with its registered address in Cricket Square, Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands, for and on behalf of itself and its Affiliates (together with its Affiliates, “Sino”). Ambrx and Sino may each be referred to herein individually as a “Party” or, collectively, as the “Parties.”
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED DATED MARCH 1, 2021 CO-DEVELOPMENT AND LICENSE...Co-Development and License Agreement • June 28th, 2021 • LianBio • Pharmaceutical preparations • New York
Contract Type FiledJune 28th, 2021 Company Industry Jurisdiction
CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201Co-Development and License Agreement • September 20th, 2019 • Innate Pharma SA • Biological products, (no disgnostic substances) • England and Wales
Contract Type FiledSeptember 20th, 2019 Company Industry JurisdictionTHIS SECOND AMENDMENT TO THE CO-DEVELOPMENT AND LICENSE AGREEMENT RELATING TO IPH2201 (this “Second Amendment”) is made and entered into as of July 26, 2019 (the “Amendment Effective Date”), by and between MedImmune Limited, a company organized under the laws of England and Wales (“MedImmune”) and Innate Pharma S.A, a company organized under the laws of France (“Innate”). MedImmune and Innate are each referred to in this Amendment as a “Party” and collectively, as the “Parties”.
Certain identified information has been excluded from this exhibit because it both (i) is not material and (ii) would be competitively harmful if publicly disclosed. Omissions are designated as [**] FIBROCELL SCIENCE, INC. AND CASTLE CREEK...Co-Development and License Agreement • August 14th, 2019 • Fibrocell Science, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 14th, 2019 Company Industry Jurisdiction
AMENDMENT NO. 1 TO CO-DEVELOPMENT AND LICENSE AGREEMENTCo-Development and License Agreement • June 14th, 2017 • Minerva Neurosciences, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJune 14th, 2017 Company Industry JurisdictionThis AMENDMENT NO. 1 TO CO-DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”), dated as of June 13, 2017 (the “Amendment Execution Date”), is made by and between Janssen Pharmaceutica NV, a corporation organized and existing under the laws of Belgium (“Janssen”) and Minerva Neurosciences, Inc., a corporation organized under the laws of the State of Delaware (“Minerva”). Janssen and Minerva are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
CO-DEVELOPMENT AND LICENSE AGREEMENTCo-Development and License Agreement • April 3rd, 2006 • GPC Biotech Ag • Pharmaceutical preparations • New York
Contract Type FiledApril 3rd, 2006 Company Industry JurisdictionThis Co-Development and License Agreement (the “Agreement”) is made and entered into effective as of December 19, 2005 (the “Effective Date”) by and between GPC Biotech AG, a German corporation, having its place of business at Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany (“GPC Biotech”); and Pharmion GmbH, a Swiss limited liability company and wholly-owned subsidiary of Pharmion Corporation, a Delaware corporation, having a place of business at Aeschenvorstadt 71, 4051 Basel, Switzerland (“Licensee”). GPC Biotech and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractCo-Development and License Agreement • August 3rd, 2016 • CytomX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 3rd, 2016 Company Industry Jurisdiction***Text Omitted and Filed Separately with the Securities and ExchangeExhibit 10.1 Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2